Description
LHC-165 is a benzonaphthyridine TLR7 agonist.
| Product Unit Size | Cost | Quantity | Stock |
|---|
LHC-165 is a benzonaphthyridine TLR7 agonist.
| Cas No. | 1258595-14-0 |
|---|---|
| Purity | ≥99% |
| Formula | C29H32F2N3O7P |
| Formula Wt. | 603.56 |
| IUPAC Name | 3-[5-amino-2-[2-[4-[2-(3,3-difluoro-3-phosphonopropoxy)ethoxy]-2-methylphenyl]ethyl]benzo[f][1,7]naphthyridin-8-yl]propanoic acid |
| Synonym | LHC165 |
| Appearance | Pale yellow powder |
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
| Info Sheet |
|---|
Zawit M, Swami U, Awada H, et al. Current status of intralesional agents in treatment of malignant melanoma. Ann Transl Med. 2021 Jun;9(12):1038. PMID: 34277838
BH3 mimetic; Bcl-2, Bxl-xl, Bcl-w inhibitor.
Phytoalexin
Nucleotide analog; RT inhibitor.
NSAID; COX-2 inhibitor.
Vitamin E component
Endogenous peptide, involved in hormone regulat...
Pyridine; PDE3 inhibitor.
Benzazepine derivative; D1 partial agonist, pot...
Methimazole prodrug; thyroid peroxidase inhibit...
Negative control for PKC activation.
Dihydropyridine; L-type and N-type Ca2+ channel...
β-adrenergic antagonist, Kv1.4 and K2P2 K+ cha...
Endogenous APP peptide cleavage product, primar...
Isoflavone found in soy; SERM.
Expectorant.
Inhibitor of CDK.
FIASMA, 5-HT3 and σ1 agonist, SERT inhibitor.<...
Cytarabine derivative, nucleoside (cytosine) an...
NSAID; COX inhibitor and HS-releasing agent.